Q2 EPS Forecast for Harmony Biosciences Raised by Analyst

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – HC Wainwright boosted their Q2 2026 EPS estimates for shares of Harmony Biosciences in a report released on Thursday, September 25th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of $1.16 per share for the quarter, up from their prior forecast of $1.01. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q3 2026 earnings at $1.25 EPS, FY2028 earnings at $7.21 EPS and FY2029 earnings at $7.43 EPS.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.10). The firm had revenue of $200.49 million for the quarter, compared to analyst estimates of $204.37 million. Harmony Biosciences had a net margin of 23.44% and a return on equity of 26.34%. The company’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.05 earnings per share. Harmony Biosciences has set its FY 2025 guidance at EPS.

Other analysts also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday. Truist Financial began coverage on shares of Harmony Biosciences in a research report on Monday, July 21st. They set a “buy” rating and a $48.00 price target on the stock. Oppenheimer began coverage on shares of Harmony Biosciences in a research report on Monday, June 2nd. They set an “outperform” rating and a $61.00 price target on the stock. Mizuho dropped their price target on shares of Harmony Biosciences from $50.00 to $35.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, Wall Street Zen upgraded shares of Harmony Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 20th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $45.50.

Harmony Biosciences Stock Up 1.7%

HRMY stock opened at $27.51 on Friday. Harmony Biosciences has a 52 week low of $26.35 and a 52 week high of $41.61. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of 8.87, a price-to-earnings-growth ratio of 0.32 and a beta of 0.84. The firm’s 50-day moving average is $34.92 and its two-hundred day moving average is $33.37. The company has a current ratio of 3.84, a quick ratio of 3.80 and a debt-to-equity ratio of 0.20.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Texas Permanent School Fund Corp grew its position in Harmony Biosciences by 28.4% during the second quarter. Texas Permanent School Fund Corp now owns 34,732 shares of the company’s stock valued at $1,098,000 after purchasing an additional 7,686 shares in the last quarter. Cim LLC grew its position in Harmony Biosciences by 5.7% during the second quarter. Cim LLC now owns 13,641 shares of the company’s stock valued at $431,000 after purchasing an additional 730 shares in the last quarter. State of Wyoming grew its position in Harmony Biosciences by 41.2% during the second quarter. State of Wyoming now owns 8,885 shares of the company’s stock valued at $281,000 after purchasing an additional 2,591 shares in the last quarter. Hohimer Wealth Management LLC purchased a new position in Harmony Biosciences during the second quarter valued at approximately $261,000. Finally, Nomura Holdings Inc. grew its position in Harmony Biosciences by 382.3% during the second quarter. Nomura Holdings Inc. now owns 422,919 shares of the company’s stock valued at $13,364,000 after purchasing an additional 335,237 shares in the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.